In partnership with

Lung Cancer

In this disease area you will find articles about this disease, including conference reports, international medical news and journal articles.

Use of prophylactic cranial irradiation for extensive-stage small-cell lung cancer may be dropping (22/8/2019) ›AstraZeneca Imfinzi combination fails advanced lung cancer study (21/8/2019) ›Neoadjuvant nivolumab/ipilimumab shows promise in resectable NSCLC (23/7/2019) ›Early results from TAK-788 in NSCLC with EGFR exon 20 insertions (23/7/2019) ›Pembrolizumab monotherapy leads to 5-year survival in some patients with NSCLC (23/7/2019) ›Repotrectinib shows encouraging safety, efficacy for patients with ROS1+ NSCLC (23/7/2019) ›Lurbinectedin shows promise as second-line therapy for SCLC (23/7/2019) ›Novel RET inhibitor BLU-667 offers promise for RET+ advanced NSCLC (23/7/2019) ›Overcoming the challenges of immunotherapy in non–small cell lung cancer (23/7/2019) ›Lung-cancer-screening eligibility should be expanded (18/7/2019) ›WHO keeps key lung cancer drugs off its essential medicines list (9/7/2019) ›Antioxidants enhance lung cancer metastasis by stabilizing BACH1 (8/7/2019) ›High prevalence of PD-L1 expression in non-small-cell lung cancer (5/7/2019) ›Lung-cancer screening may be warranted in bladder-cancer patients (2/7/2019) ›Brain irradiation as treatment option (1/7/2019) ›Other I-O combinations (1/7/2019) ›Predictive diagnostics for I-O (1/7/2019) ›Molecular characteristics of SCLC (1/7/2019) ›Electromagnetic navigation bronchoscopy (1/7/2019) ›Immunotherapy in SCLC: trial data (1/7/2019) ›Post-discontinuation immunotherapy in PACIFIC (1/7/2019) ›Treatment options in early NSCLC (1/7/2019) ›Systemic therapy of brain metastases (1/7/2019) ›Experiences from France (1/7/2019) ›Experiences from Germany (1/7/2019) ›I-O monotherapy (1/7/2019) ›Genomic and immune profiling (1/7/2019) ›Incidence and local treatment (1/7/2019) ›Tumour, node, and metastasis (TNM) staging system (1/7/2019) ›Post-study immunotherapy in MYSTIC (1/7/2019) ›How can societies help to implement personalised treatment? (1/7/2019) ›Combo I-O plus chemotherapy (1/7/2019) ›Lung cancer radiotherapy tied to higher cardiac mortality (18/6/2019) ›Broadening eligibility for lung cancer trials could have huge impact (5/6/2019) ›Pembrolizumab quadruples survival in selected advanced non-small cell lung cancer patients (3/6/2019) ›Atezolizumab added to chemo ups survival in lung cancer (31/5/2019) ›Longer lung-cancer-screening intervals may sometimes be OK (27/5/2019) ›Vein-first ligation in lung-cancer surgery may increase survival (14/5/2019) ›New technique for minimally invasive lung cancer surgery promising (10/5/2019) ›Deep-learning model may help predict NSCLC outcomes, survival (30/4/2019) ›Higher radiation doses tied to increased longevity in node-negative lung cancer (30/4/2019) ›Lung-cancer survival worse in patients with pulmonary fibrosis (25/4/2019) ›Electromagnetic navigation: an instant hit? (11/4/2019) ›Survival benefit persists despite post-discontinuation therapy (11/4/2019) ›Post-study immunotherapy confounds primary survival outcome (11/4/2019) ›Immunotherapy in elderly: diverse findings across the globe (11/4/2019) ›Comprehensive profiling in localised stage lung cancer (11/4/2019) ›Pembrolizumab may help some with advanced non-small-cell lung cancer (2/4/2019) ›Next-generation sequencing assay detects genetic variants driving cancer, resistance in NSCLC (2/4/2019) ›Cranial irradiation doesn't boost survival in locally advanced lung cancer (26/3/2019) ›Lung-cancer screens effective in asbestos-exposed smokers (14/3/2019) ›Liquid biopsy on par with tissue testing in advanced lung cancer (5/3/2019) ›Stereotactic ablative radiotherapy tops for inoperable early non-small-cell lung cancer (21/2/2019) ›It's never too late to quit smoking before lung surgery (16/1/2019) ›Lung cancer screening complications may be higher than expected (14/1/2019) ›Prognostic value of distant organ-specific metastases in newly diagnosed lung neuroendocrine tumours (26/9/2018) ›Unmet needs in surgical management of malignant pleural mesothelioma (26/9/2018) ›Spread through air spaces is prognostic in lung neuroendocrine tumours (26/9/2018) ›Potential for brigatinib as a first-line treatment option for ALK+ non-small-cell lung cancer (26/9/2018) ›New standard of care in extensive-stage small-cell lung cancer (26/9/2018) ›Crizotinib-treated ALK IHC-positive advanced NSCLC is associated with an unfavourable prognosis when FISH negative (26/9/2018) ›Interview with IASCL President (26/9/2018) ›Combination therapies: Where are we in 2018? (26/9/2018) ›No progression-free survival benefit with nintedanib plus pemetrexed/cisplatin for malignant pleural mesothelioma of epithelial subtype (26/9/2018) ›Effects of dose modifications on safety and efficacy of dacomitinib for EGFR-mutant non-small-cell lung cancer (26/9/2018) ›Avelumab vs docetaxel for previously treated advanced non-small-cell lung cancer (26/9/2018) ›Central nervous system activity of ramucirumab + osimertinib in patients with advanced T790M-positive EGFR-mutant non-small-cell lung cancer (26/9/2018) ›Osimertinib and RET inhibitor BLU-667 in an EGFR-mutant patient with acquired RET rearrangement (26/9/2018) ›Durvalumab after chemoradiotherapy extends OS in stage 3, unresectable non-small-cell lung cancer (26/9/2018) ›Small-cell lung cancer circulating tumour cell derived explants (26/9/2018) ›Entrectinib treatment in patients with ROS1+ NSCLC (26/9/2018) ›Benefits of chest CT screening (26/9/2018) ›PD-L1 expression in untreated EGFR-mutant non-small-cell lung cancer and response to osimertinib (26/9/2018) ›Next generation immunotherapy in non-small-cell lung cancer (26/9/2018) ›Patient-reported outcomes of first-line nivolumab + ipilimumab in high tumour mutational burden advanced non-small-cell lung cancer (26/9/2018) ›Accumulation of concomitant mutations involved in drug resistance in sequential ALK TKI treatments of ALK-positive NSCLC (26/9/2018) ›Angiogenic and stromal biomarkers in malignant mesothelioma (26/9/2018) ›Choice of taxane and addition of pembrolizumab for metastatic squamous non-small-cell lung cancer (26/9/2018) ›

Highlighted disease areas

Atrial fibrillation ›

Lung Cancer ›

Full list of disease areas ›

Subscribe for free ›

Stay up-to-date with Medicom. Subscribe to the Medicom Conference Reports and newsletter.

About us ›

Medicom provides the highest quality medical information and tools to international medical professionals.

BACK TO TOP